Baxter International Inc (NYSE:BAX) has received an average recommendation of “Buy” from the seventeen analysts that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $68.38.
A number of equities research analysts recently commented on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price objective on the stock in a report on Tuesday, October 24th. BMO Capital Markets reaffirmed a “buy” rating and issued a $70.00 target price on shares of Baxter International in a research report on Friday, October 13th. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Morgan Stanley raised their target price on shares of Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $60.00 target price on shares of Baxter International in a research report on Tuesday, October 3rd.
In other news, SVP Giuseppe Accogli sold 28,641 shares of Baxter International stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeanne K. Mason sold 33,350 shares of Baxter International stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the completion of the transaction, the senior vice president now directly owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,061,991 shares of company stock valued at $325,245,035. 0.05% of the stock is owned by insiders.
Shares of Baxter International (NYSE BAX) opened at $69.20 on Friday. Baxter International has a twelve month low of $45.47 and a twelve month high of $69.65. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. The company has a market cap of $37,830.00, a price-to-earnings ratio of 37.41, a P/E/G ratio of 2.05 and a beta of 0.69.
Baxter International (NYSE:BAX) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The business had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period last year, the business posted $0.56 earnings per share. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. analysts predict that Baxter International will post 2.43 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date was Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is currently 34.59%.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.